Literature DB >> 15547747

Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients.

Yoriko Murata1, Yasuhiro Ogawa, Shoji Yoshida, Kei Kubota, Satoshi Itoh, Mitsutaka Fukumoto, Akihito Nishioka, Toshiaki Moriki, Hironori Maeda, Yosuke Tanaka.   

Abstract

This study was performed to evaluate the utility of initial MRI in predicting the extent of residual disease following neoadjuvant chemotherapy (NAC). The study population consisted of 70 patients with breast cancer (unilateral, n=69; bilateral, n=1) (mean age 51 years) who underwent magnetic resonance imaging (MRI) with gadolinium enhancement both before and after NAC. Basic NAC was comprised of cyclophosphamide, pirarubicin, and 5-fluorouracil. MRI features were compared with pathological diagnosis following surgery. MRI features of breast cancer before NAC were classified as either solitary nodular (SN) (n=33) (47%), or multiple nodular and/or unlocalized dendritic (MN/UD) (n=38) (53%). MRI typing was independent of NAC in 68 tumors (SN, n=32; MN/UD, n=36) (96%, p<0.0001). All except one of the 33 SN tumors (97%) displayed negative margins. In addition, 5 of the 33 SN tumors (15%) displayed pathological complete response (pCR). Conversely, all 5 requiring total glandectomy due to wide infiltration and all except one of the 17 (94%) displaying positive margins necessitating extended resection were classified as MN/UD. Only SN-type tumors on initial MRI have the possibility of pCR after NAC. MN/UD tumors could possess margins necessitating expanded excision or total glandectomy. Morphological concepts based on MRI can prove useful in surgical planning and predicting the extent of residual disease after NAC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547747

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy.

Authors:  Takayoshi Uematsu; Masako Kasami; Sachiko Yuen
Journal:  Eur Radiol       Date:  2010-05-09       Impact factor: 5.315

2.  Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.

Authors:  Yanbo Li; Yongzi Chen; Rui Zhao; Yu Ji; Junnan Li; Ying Zhang; Hong Lu
Journal:  Eur Radiol       Date:  2021-11-12       Impact factor: 7.034

3.  Diffusion-weighted magnetic resonance imaging for assessment after neoadjuvant chemotherapy in breast cancer, based on morphological concepts.

Authors:  Yoriko Murata; Kei Kubota; Norihiko Hamada; Kana Miyatake; Michiko Tadokoro; Kimiko Nakatani; Hironobu Ue; Kazuhiro Tsuzuki; Akihito Nishioka; Mitsuko Iguchi; Hironobu Maeda; Yasuhiro Ogawa
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

4.  Early prediction of response to neoadjuvant chemotherapy for locally advanced breast cancer using MRI.

Authors:  Mariko Kawamura; Hiroko Satake; Satoko Ishigaki; Akiko Nishio; Masataka Sawaki; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

5.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

6.  Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography.

Authors:  Hitomi Iwasa; Kei Kubota; Norihiko Hamada; Munenobu Nogami; Akihito Nishioka
Journal:  Oncol Rep       Date:  2014-02-18       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.